May 28, 2015 / 5:12 AM / 2 years ago

BRIEF-Tigenix says stem cell sepsis treatment passes stage I trial

May 28 (Reuters) - Tigenix Nv

* Safety and tolerability of Cx611 confirmed in phase I sepsis challenge trial

* Cx611 is an intravenously-administered product of allogeneic expanded adipose-derived stem cells

* Is currently developing Cx611 for patients with early rheumatoid arthritis and for patients with severe sepsis Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below